Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxyamine hydrochloride - TRACON Pharmaceuticals

Drug Profile

Methoxyamine hydrochloride - TRACON Pharmaceuticals

Alternative Names: Methoxyamine - TRACON; TRC 102

Latest Information Update: 05 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TRACON Pharmaceuticals
  • Developer Case Western Reserve University; National Cancer Institute (USA); TRACON Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Mesothelioma
  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 02 Jul 2019 TRC 102 is still in phase I trials for Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (TRACON pipeline - July 2019)
  • 02 Jul 2019 TRC 102 is still in phase I trials for Solid tumours (Combination therapy, Late-stage disease) in USA (TRACON pipeline - July 2019)
  • 28 Jun 2019 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Second-line therapy or greater) in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top